Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to intimation dated 24th February,2025, Medi-Caps has informed that the United States Food & Drug Administration (USFDA) conducted an inspection at the manufacturing facility of Wholly Owned Subsidiary Company, Medgel at Pithampur, Madhya Pradesh, from 17th to 21st February, 2025 and it has informed that the company has received a communication from US FDA indicating that the inspection classification of this facility as ‘Voluntary Action Indicated’ (VAI). FDA has concluded that this inspection is ‘closed’ under 21 CFR 20.64 (d) (3). The above information will also be available on the website of the Company at www.medicaps.com.
The above information is a part of company’s filings submitted to BSE.
